nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosamprenavir—CYP3A4—Thiotepa—urinary bladder cancer	0.282	0.687	CbGbCtD
Fosamprenavir—CYP3A4—Etoposide—urinary bladder cancer	0.0765	0.186	CbGbCtD
Fosamprenavir—CYP3A4—Doxorubicin—urinary bladder cancer	0.0522	0.127	CbGbCtD
Fosamprenavir—Diarrhoea—Mitomycin—urinary bladder cancer	0.00305	0.00517	CcSEcCtD
Fosamprenavir—Hyperglycaemia—Gemcitabine—urinary bladder cancer	0.00299	0.00507	CcSEcCtD
Fosamprenavir—Dizziness—Mitomycin—urinary bladder cancer	0.00294	0.005	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Gemcitabine—urinary bladder cancer	0.00293	0.00497	CcSEcCtD
Fosamprenavir—Cardiac disorder—Thiotepa—urinary bladder cancer	0.00292	0.00497	CcSEcCtD
Fosamprenavir—Acute coronary syndrome—Gemcitabine—urinary bladder cancer	0.00291	0.00494	CcSEcCtD
Fosamprenavir—Myocardial infarction—Gemcitabine—urinary bladder cancer	0.00289	0.00491	CcSEcCtD
Fosamprenavir—Alanine aminotransferase increased—Etoposide—urinary bladder cancer	0.00289	0.0049	CcSEcCtD
Fosamprenavir—Acute coronary syndrome—Fluorouracil—urinary bladder cancer	0.00286	0.00486	CcSEcCtD
Fosamprenavir—Immune system disorder—Thiotepa—urinary bladder cancer	0.00285	0.00483	CcSEcCtD
Fosamprenavir—Myocardial infarction—Fluorouracil—urinary bladder cancer	0.00285	0.00483	CcSEcCtD
Fosamprenavir—Vomiting—Mitomycin—urinary bladder cancer	0.00283	0.00481	CcSEcCtD
Fosamprenavir—Rash—Mitomycin—urinary bladder cancer	0.00281	0.00477	CcSEcCtD
Fosamprenavir—Dermatitis—Mitomycin—urinary bladder cancer	0.0028	0.00476	CcSEcCtD
Fosamprenavir—Headache—Mitomycin—urinary bladder cancer	0.00279	0.00474	CcSEcCtD
Fosamprenavir—Inflammation—Methotrexate—urinary bladder cancer	0.00278	0.00473	CcSEcCtD
Fosamprenavir—Malnutrition—Thiotepa—urinary bladder cancer	0.00274	0.00466	CcSEcCtD
Fosamprenavir—Acute coronary syndrome—Cisplatin—urinary bladder cancer	0.00271	0.00461	CcSEcCtD
Fosamprenavir—Myocardial infarction—Cisplatin—urinary bladder cancer	0.0027	0.00458	CcSEcCtD
Fosamprenavir—Haemoglobin—Gemcitabine—urinary bladder cancer	0.00266	0.00452	CcSEcCtD
Fosamprenavir—Haemorrhage—Gemcitabine—urinary bladder cancer	0.00265	0.0045	CcSEcCtD
Fosamprenavir—Neutropenia—Etoposide—urinary bladder cancer	0.00264	0.00449	CcSEcCtD
Fosamprenavir—Nausea—Mitomycin—urinary bladder cancer	0.00264	0.00449	CcSEcCtD
Fosamprenavir—Haemoglobin—Fluorouracil—urinary bladder cancer	0.00262	0.00445	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Gemcitabine—urinary bladder cancer	0.00262	0.00444	CcSEcCtD
Fosamprenavir—Haemorrhage—Fluorouracil—urinary bladder cancer	0.00261	0.00443	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Gemcitabine—urinary bladder cancer	0.0026	0.00442	CcSEcCtD
Fosamprenavir—Inflammation—Epirubicin—urinary bladder cancer	0.0026	0.00442	CcSEcCtD
Fosamprenavir—Urethral disorder—Gemcitabine—urinary bladder cancer	0.0026	0.00441	CcSEcCtD
Fosamprenavir—Erythema multiforme—Gemcitabine—urinary bladder cancer	0.00251	0.00426	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Etoposide—urinary bladder cancer	0.0025	0.00424	CcSEcCtD
Fosamprenavir—Acute coronary syndrome—Etoposide—urinary bladder cancer	0.00249	0.00422	CcSEcCtD
Fosamprenavir—Myocardial infarction—Etoposide—urinary bladder cancer	0.00247	0.0042	CcSEcCtD
Fosamprenavir—Cardiac disorder—Gemcitabine—urinary bladder cancer	0.00246	0.00418	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Cisplatin—urinary bladder cancer	0.00244	0.00414	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Cisplatin—urinary bladder cancer	0.00243	0.00412	CcSEcCtD
Fosamprenavir—Urethral disorder—Cisplatin—urinary bladder cancer	0.00242	0.00411	CcSEcCtD
Fosamprenavir—Inflammation—Doxorubicin—urinary bladder cancer	0.00241	0.00409	CcSEcCtD
Fosamprenavir—Immune system disorder—Gemcitabine—urinary bladder cancer	0.00239	0.00407	CcSEcCtD
Fosamprenavir—Myalgia—Thiotepa—urinary bladder cancer	0.00234	0.00397	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.00232	0.00394	CcSEcCtD
Fosamprenavir—Cardiac disorder—Cisplatin—urinary bladder cancer	0.00229	0.00389	CcSEcCtD
Fosamprenavir—Diabetes mellitus—Methotrexate—urinary bladder cancer	0.00225	0.00383	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Etoposide—urinary bladder cancer	0.00224	0.0038	CcSEcCtD
Fosamprenavir—Immune system disorder—Cisplatin—urinary bladder cancer	0.00223	0.00379	CcSEcCtD
Fosamprenavir—Urethral disorder—Etoposide—urinary bladder cancer	0.00222	0.00377	CcSEcCtD
Fosamprenavir—Nervous system disorder—Thiotepa—urinary bladder cancer	0.0022	0.00373	CcSEcCtD
Fosamprenavir—Skin disorder—Thiotepa—urinary bladder cancer	0.00217	0.00369	CcSEcCtD
Fosamprenavir—Malnutrition—Cisplatin—urinary bladder cancer	0.00215	0.00365	CcSEcCtD
Fosamprenavir—Erythema multiforme—Etoposide—urinary bladder cancer	0.00214	0.00363	CcSEcCtD
Fosamprenavir—Anorexia—Thiotepa—urinary bladder cancer	0.00213	0.00362	CcSEcCtD
Fosamprenavir—Flatulence—Cisplatin—urinary bladder cancer	0.00212	0.0036	CcSEcCtD
Fosamprenavir—Diabetes mellitus—Epirubicin—urinary bladder cancer	0.00211	0.00358	CcSEcCtD
Fosamprenavir—Cardiac disorder—Etoposide—urinary bladder cancer	0.0021	0.00357	CcSEcCtD
Fosamprenavir—Immune system disorder—Etoposide—urinary bladder cancer	0.00204	0.00347	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.00204	0.00346	CcSEcCtD
Fosamprenavir—Myalgia—Gemcitabine—urinary bladder cancer	0.00196	0.00334	CcSEcCtD
Fosamprenavir—Diabetes mellitus—Doxorubicin—urinary bladder cancer	0.00195	0.00331	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.00195	0.00331	CcSEcCtD
Fosamprenavir—Decreased appetite—Thiotepa—urinary bladder cancer	0.00195	0.0033	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00193	0.00328	CcSEcCtD
Fosamprenavir—Myalgia—Fluorouracil—urinary bladder cancer	0.00193	0.00328	CcSEcCtD
Fosamprenavir—Fatigue—Thiotepa—urinary bladder cancer	0.00193	0.00328	CcSEcCtD
Fosamprenavir—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.00185	0.00314	CcSEcCtD
Fosamprenavir—Myalgia—Cisplatin—urinary bladder cancer	0.00183	0.00311	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.00183	0.00311	CcSEcCtD
Fosamprenavir—Skin disorder—Gemcitabine—urinary bladder cancer	0.00183	0.00311	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.00182	0.00309	CcSEcCtD
Fosamprenavir—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00182	0.00308	CcSEcCtD
Fosamprenavir—Anorexia—Gemcitabine—urinary bladder cancer	0.0018	0.00305	CcSEcCtD
Fosamprenavir—Abdominal pain—Thiotepa—urinary bladder cancer	0.00177	0.00301	CcSEcCtD
Fosamprenavir—Body temperature increased—Thiotepa—urinary bladder cancer	0.00177	0.00301	CcSEcCtD
Fosamprenavir—Anorexia—Fluorouracil—urinary bladder cancer	0.00177	0.003	CcSEcCtD
Fosamprenavir—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00172	0.00292	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.00172	0.00291	CcSEcCtD
Fosamprenavir—Skin disorder—Cisplatin—urinary bladder cancer	0.00171	0.0029	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.00169	0.00286	CcSEcCtD
Fosamprenavir—Anorexia—Cisplatin—urinary bladder cancer	0.00167	0.00284	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00167	0.00283	CcSEcCtD
Fosamprenavir—Aspartate aminotransferase increased—Epirubicin—urinary bladder cancer	0.00165	0.0028	CcSEcCtD
Fosamprenavir—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00165	0.0028	CcSEcCtD
Fosamprenavir—Decreased appetite—Gemcitabine—urinary bladder cancer	0.00164	0.00278	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00163	0.00276	CcSEcCtD
Fosamprenavir—Fatigue—Gemcitabine—urinary bladder cancer	0.00162	0.00276	CcSEcCtD
Fosamprenavir—Gastritis—Epirubicin—urinary bladder cancer	0.00162	0.00276	CcSEcCtD
Fosamprenavir—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.00162	0.00275	CcSEcCtD
Fosamprenavir—Decreased appetite—Fluorouracil—urinary bladder cancer	0.00161	0.00273	CcSEcCtD
Fosamprenavir—Asthenia—Thiotepa—urinary bladder cancer	0.00161	0.00273	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.0016	0.00272	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.0016	0.00271	CcSEcCtD
Fosamprenavir—Neutropenia—Methotrexate—urinary bladder cancer	0.00158	0.00269	CcSEcCtD
Fosamprenavir—Pruritus—Thiotepa—urinary bladder cancer	0.00158	0.00269	CcSEcCtD
Fosamprenavir—Skin disorder—Etoposide—urinary bladder cancer	0.00156	0.00265	CcSEcCtD
Fosamprenavir—Anorexia—Etoposide—urinary bladder cancer	0.00153	0.0026	CcSEcCtD
Fosamprenavir—Diarrhoea—Thiotepa—urinary bladder cancer	0.00153	0.0026	CcSEcCtD
Fosamprenavir—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.00153	0.00259	CcSEcCtD
Fosamprenavir—Decreased appetite—Cisplatin—urinary bladder cancer	0.00153	0.00259	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00152	0.00257	CcSEcCtD
Fosamprenavir—Gastritis—Doxorubicin—urinary bladder cancer	0.0015	0.00255	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.0015	0.00254	CcSEcCtD
Fosamprenavir—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.0015	0.00254	CcSEcCtD
Fosamprenavir—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00149	0.00253	CcSEcCtD
Fosamprenavir—Neutropenia—Epirubicin—urinary bladder cancer	0.00148	0.00252	CcSEcCtD
Fosamprenavir—Dizziness—Thiotepa—urinary bladder cancer	0.00148	0.00251	CcSEcCtD
Fosamprenavir—Body temperature increased—Fluorouracil—urinary bladder cancer	0.00146	0.00249	CcSEcCtD
Fosamprenavir—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.00143	0.00243	CcSEcCtD
Fosamprenavir—Vomiting—Thiotepa—urinary bladder cancer	0.00142	0.00242	CcSEcCtD
Fosamprenavir—Rash—Thiotepa—urinary bladder cancer	0.00141	0.0024	CcSEcCtD
Fosamprenavir—Dermatitis—Thiotepa—urinary bladder cancer	0.00141	0.00239	CcSEcCtD
Fosamprenavir—Headache—Thiotepa—urinary bladder cancer	0.0014	0.00238	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.0014	0.00238	CcSEcCtD
Fosamprenavir—Decreased appetite—Etoposide—urinary bladder cancer	0.0014	0.00237	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00139	0.00236	CcSEcCtD
Fosamprenavir—Body temperature increased—Cisplatin—urinary bladder cancer	0.00139	0.00236	CcSEcCtD
Fosamprenavir—Fatigue—Etoposide—urinary bladder cancer	0.00139	0.00235	CcSEcCtD
Fosamprenavir—Neutropenia—Doxorubicin—urinary bladder cancer	0.00137	0.00233	CcSEcCtD
Fosamprenavir—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00136	0.00232	CcSEcCtD
Fosamprenavir—Haemoglobin—Methotrexate—urinary bladder cancer	0.00136	0.00231	CcSEcCtD
Fosamprenavir—Haemorrhage—Methotrexate—urinary bladder cancer	0.00136	0.0023	CcSEcCtD
Fosamprenavir—Asthenia—Gemcitabine—urinary bladder cancer	0.00135	0.00229	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.00134	0.00227	CcSEcCtD
Fosamprenavir—Pruritus—Gemcitabine—urinary bladder cancer	0.00133	0.00226	CcSEcCtD
Fosamprenavir—Nausea—Thiotepa—urinary bladder cancer	0.00133	0.00226	CcSEcCtD
Fosamprenavir—Urethral disorder—Methotrexate—urinary bladder cancer	0.00133	0.00226	CcSEcCtD
Fosamprenavir—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.00132	0.00225	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.00132	0.00223	CcSEcCtD
Fosamprenavir—Pruritus—Fluorouracil—urinary bladder cancer	0.00131	0.00222	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.0013	0.0022	CcSEcCtD
Fosamprenavir—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00129	0.0022	CcSEcCtD
Fosamprenavir—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00129	0.00219	CcSEcCtD
Fosamprenavir—Erythema multiforme—Methotrexate—urinary bladder cancer	0.00128	0.00218	CcSEcCtD
Fosamprenavir—Haemoglobin—Epirubicin—urinary bladder cancer	0.00128	0.00217	CcSEcCtD
Fosamprenavir—Body temperature increased—Etoposide—urinary bladder cancer	0.00127	0.00216	CcSEcCtD
Fosamprenavir—Abdominal pain—Etoposide—urinary bladder cancer	0.00127	0.00216	CcSEcCtD
Fosamprenavir—Haemorrhage—Epirubicin—urinary bladder cancer	0.00127	0.00215	CcSEcCtD
Fosamprenavir—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00127	0.00215	CcSEcCtD
Fosamprenavir—Asthenia—Cisplatin—urinary bladder cancer	0.00126	0.00214	CcSEcCtD
Fosamprenavir—Cardiac disorder—Methotrexate—urinary bladder cancer	0.00126	0.00214	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.00125	0.00213	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.00125	0.00212	CcSEcCtD
Fosamprenavir—Urethral disorder—Epirubicin—urinary bladder cancer	0.00124	0.00211	CcSEcCtD
Fosamprenavir—Immune system disorder—Methotrexate—urinary bladder cancer	0.00122	0.00208	CcSEcCtD
Fosamprenavir—Dizziness—Fluorouracil—urinary bladder cancer	0.00122	0.00208	CcSEcCtD
Fosamprenavir—Diarrhoea—Cisplatin—urinary bladder cancer	0.0012	0.00204	CcSEcCtD
Fosamprenavir—Erythema multiforme—Epirubicin—urinary bladder cancer	0.0012	0.00204	CcSEcCtD
Fosamprenavir—Vomiting—Gemcitabine—urinary bladder cancer	0.0012	0.00203	CcSEcCtD
Fosamprenavir—Rash—Gemcitabine—urinary bladder cancer	0.00119	0.00202	CcSEcCtD
Fosamprenavir—Dermatitis—Gemcitabine—urinary bladder cancer	0.00119	0.00201	CcSEcCtD
Fosamprenavir—Hypersensitivity—Etoposide—urinary bladder cancer	0.00118	0.00201	CcSEcCtD
Fosamprenavir—Malnutrition—Methotrexate—urinary bladder cancer	0.00118	0.002	CcSEcCtD
Fosamprenavir—Haemoglobin—Doxorubicin—urinary bladder cancer	0.00118	0.002	CcSEcCtD
Fosamprenavir—Headache—Gemcitabine—urinary bladder cancer	0.00118	0.002	CcSEcCtD
Fosamprenavir—Cardiac disorder—Epirubicin—urinary bladder cancer	0.00118	0.002	CcSEcCtD
Fosamprenavir—Vomiting—Fluorouracil—urinary bladder cancer	0.00118	0.002	CcSEcCtD
Fosamprenavir—Haemorrhage—Doxorubicin—urinary bladder cancer	0.00117	0.00199	CcSEcCtD
Fosamprenavir—Rash—Fluorouracil—urinary bladder cancer	0.00117	0.00198	CcSEcCtD
Fosamprenavir—Dermatitis—Fluorouracil—urinary bladder cancer	0.00117	0.00198	CcSEcCtD
Fosamprenavir—Headache—Fluorouracil—urinary bladder cancer	0.00116	0.00197	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.00116	0.00197	CcSEcCtD
Fosamprenavir—Asthenia—Etoposide—urinary bladder cancer	0.00115	0.00196	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.00115	0.00196	CcSEcCtD
Fosamprenavir—Urethral disorder—Doxorubicin—urinary bladder cancer	0.00115	0.00195	CcSEcCtD
Fosamprenavir—Immune system disorder—Epirubicin—urinary bladder cancer	0.00115	0.00195	CcSEcCtD
Fosamprenavir—Pruritus—Etoposide—urinary bladder cancer	0.00114	0.00193	CcSEcCtD
Fosamprenavir—Nausea—Gemcitabine—urinary bladder cancer	0.00112	0.0019	CcSEcCtD
Fosamprenavir—Vomiting—Cisplatin—urinary bladder cancer	0.00112	0.0019	CcSEcCtD
Fosamprenavir—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.00111	0.00188	CcSEcCtD
Fosamprenavir—Rash—Cisplatin—urinary bladder cancer	0.00111	0.00188	CcSEcCtD
Fosamprenavir—Dermatitis—Cisplatin—urinary bladder cancer	0.00111	0.00188	CcSEcCtD
Fosamprenavir—Malnutrition—Epirubicin—urinary bladder cancer	0.0011	0.00188	CcSEcCtD
Fosamprenavir—Diarrhoea—Etoposide—urinary bladder cancer	0.0011	0.00187	CcSEcCtD
Fosamprenavir—Nausea—Fluorouracil—urinary bladder cancer	0.0011	0.00187	CcSEcCtD
Fosamprenavir—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.00109	0.00185	CcSEcCtD
Fosamprenavir—Flatulence—Epirubicin—urinary bladder cancer	0.00109	0.00185	CcSEcCtD
Fosamprenavir—Dizziness—Etoposide—urinary bladder cancer	0.00106	0.00181	CcSEcCtD
Fosamprenavir—Immune system disorder—Doxorubicin—urinary bladder cancer	0.00106	0.0018	CcSEcCtD
Fosamprenavir—Nausea—Cisplatin—urinary bladder cancer	0.00104	0.00177	CcSEcCtD
Fosamprenavir—Vomiting—Etoposide—urinary bladder cancer	0.00102	0.00174	CcSEcCtD
Fosamprenavir—Malnutrition—Doxorubicin—urinary bladder cancer	0.00102	0.00174	CcSEcCtD
Fosamprenavir—Rash—Etoposide—urinary bladder cancer	0.00101	0.00172	CcSEcCtD
Fosamprenavir—Dermatitis—Etoposide—urinary bladder cancer	0.00101	0.00172	CcSEcCtD
Fosamprenavir—Headache—Etoposide—urinary bladder cancer	0.00101	0.00171	CcSEcCtD
Fosamprenavir—Flatulence—Doxorubicin—urinary bladder cancer	0.00101	0.00171	CcSEcCtD
Fosamprenavir—Myalgia—Methotrexate—urinary bladder cancer	0.001	0.00171	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000998	0.00169	CcSEcCtD
Fosamprenavir—Nausea—Etoposide—urinary bladder cancer	0.000955	0.00162	CcSEcCtD
Fosamprenavir—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000945	0.0016	CcSEcCtD
Fosamprenavir—Myalgia—Epirubicin—urinary bladder cancer	0.00094	0.0016	CcSEcCtD
Fosamprenavir—Skin disorder—Methotrexate—urinary bladder cancer	0.000936	0.00159	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000934	0.00159	CcSEcCtD
Fosamprenavir—Anorexia—Methotrexate—urinary bladder cancer	0.000918	0.00156	CcSEcCtD
Fosamprenavir—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000884	0.0015	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000878	0.00149	CcSEcCtD
Fosamprenavir—Skin disorder—Epirubicin—urinary bladder cancer	0.000876	0.00149	CcSEcCtD
Fosamprenavir—Myalgia—Doxorubicin—urinary bladder cancer	0.00087	0.00148	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000864	0.00147	CcSEcCtD
Fosamprenavir—Anorexia—Epirubicin—urinary bladder cancer	0.000859	0.00146	CcSEcCtD
Fosamprenavir—Decreased appetite—Methotrexate—urinary bladder cancer	0.000837	0.00142	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000832	0.00141	CcSEcCtD
Fosamprenavir—Fatigue—Methotrexate—urinary bladder cancer	0.00083	0.00141	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000821	0.00139	CcSEcCtD
Fosamprenavir—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000818	0.00139	CcSEcCtD
Fosamprenavir—Skin disorder—Doxorubicin—urinary bladder cancer	0.00081	0.00138	CcSEcCtD
Fosamprenavir—Anorexia—Doxorubicin—urinary bladder cancer	0.000795	0.00135	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000788	0.00134	CcSEcCtD
Fosamprenavir—Decreased appetite—Epirubicin—urinary bladder cancer	0.000784	0.00133	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000778	0.00132	CcSEcCtD
Fosamprenavir—Fatigue—Epirubicin—urinary bladder cancer	0.000777	0.00132	CcSEcCtD
Fosamprenavir—Body temperature increased—Methotrexate—urinary bladder cancer	0.000761	0.00129	CcSEcCtD
Fosamprenavir—Abdominal pain—Methotrexate—urinary bladder cancer	0.000761	0.00129	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.00076	0.00129	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000737	0.00125	CcSEcCtD
Fosamprenavir—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000725	0.00123	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.00072	0.00122	CcSEcCtD
Fosamprenavir—Fatigue—Doxorubicin—urinary bladder cancer	0.000719	0.00122	CcSEcCtD
Fosamprenavir—Body temperature increased—Epirubicin—urinary bladder cancer	0.000713	0.00121	CcSEcCtD
Fosamprenavir—Abdominal pain—Epirubicin—urinary bladder cancer	0.000713	0.00121	CcSEcCtD
Fosamprenavir—Hypersensitivity—Methotrexate—urinary bladder cancer	0.00071	0.00121	CcSEcCtD
Fosamprenavir—Asthenia—Methotrexate—urinary bladder cancer	0.000691	0.00117	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000682	0.00116	CcSEcCtD
Fosamprenavir—Pruritus—Methotrexate—urinary bladder cancer	0.000682	0.00116	CcSEcCtD
Fosamprenavir—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000664	0.00113	CcSEcCtD
Fosamprenavir—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000659	0.00112	CcSEcCtD
Fosamprenavir—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000659	0.00112	CcSEcCtD
Fosamprenavir—Diarrhoea—Methotrexate—urinary bladder cancer	0.000659	0.00112	CcSEcCtD
Fosamprenavir—Asthenia—Epirubicin—urinary bladder cancer	0.000647	0.0011	CcSEcCtD
Fosamprenavir—Pruritus—Epirubicin—urinary bladder cancer	0.000638	0.00108	CcSEcCtD
Fosamprenavir—Dizziness—Methotrexate—urinary bladder cancer	0.000637	0.00108	CcSEcCtD
Fosamprenavir—Diarrhoea—Epirubicin—urinary bladder cancer	0.000617	0.00105	CcSEcCtD
Fosamprenavir—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000615	0.00104	CcSEcCtD
Fosamprenavir—Vomiting—Methotrexate—urinary bladder cancer	0.000612	0.00104	CcSEcCtD
Fosamprenavir—Rash—Methotrexate—urinary bladder cancer	0.000607	0.00103	CcSEcCtD
Fosamprenavir—Dermatitis—Methotrexate—urinary bladder cancer	0.000607	0.00103	CcSEcCtD
Fosamprenavir—Headache—Methotrexate—urinary bladder cancer	0.000603	0.00102	CcSEcCtD
Fosamprenavir—Asthenia—Doxorubicin—urinary bladder cancer	0.000598	0.00102	CcSEcCtD
Fosamprenavir—Dizziness—Epirubicin—urinary bladder cancer	0.000596	0.00101	CcSEcCtD
Fosamprenavir—Pruritus—Doxorubicin—urinary bladder cancer	0.00059	0.001	CcSEcCtD
Fosamprenavir—Vomiting—Epirubicin—urinary bladder cancer	0.000573	0.000973	CcSEcCtD
Fosamprenavir—Nausea—Methotrexate—urinary bladder cancer	0.000572	0.000972	CcSEcCtD
Fosamprenavir—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000571	0.000969	CcSEcCtD
Fosamprenavir—Rash—Epirubicin—urinary bladder cancer	0.000568	0.000965	CcSEcCtD
Fosamprenavir—Dermatitis—Epirubicin—urinary bladder cancer	0.000568	0.000964	CcSEcCtD
Fosamprenavir—Headache—Epirubicin—urinary bladder cancer	0.000565	0.000959	CcSEcCtD
Fosamprenavir—Dizziness—Doxorubicin—urinary bladder cancer	0.000552	0.000937	CcSEcCtD
Fosamprenavir—Nausea—Epirubicin—urinary bladder cancer	0.000535	0.000909	CcSEcCtD
Fosamprenavir—Vomiting—Doxorubicin—urinary bladder cancer	0.00053	0.0009	CcSEcCtD
Fosamprenavir—Rash—Doxorubicin—urinary bladder cancer	0.000526	0.000893	CcSEcCtD
Fosamprenavir—Dermatitis—Doxorubicin—urinary bladder cancer	0.000525	0.000892	CcSEcCtD
Fosamprenavir—Headache—Doxorubicin—urinary bladder cancer	0.000523	0.000887	CcSEcCtD
Fosamprenavir—Nausea—Doxorubicin—urinary bladder cancer	0.000495	0.000841	CcSEcCtD
